Pharmaceutical composition
    1.
    发明申请
    Pharmaceutical composition 审中-公开
    药物组成

    公开(公告)号:US20070231382A1

    公开(公告)日:2007-10-04

    申请号:US11804284

    申请日:2007-05-17

    IPC分类号: A61K9/20

    CPC分类号: A61K31/196

    摘要: Disclosed herein are tablets and methods of treatment comprising the administration of such tablets. The tablets are immediate release tablets that comprise about 400 mg of 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof, where the 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof comprises between 60 and 70% by weight of the tablet. The methods involve the administration of the tablets of the invention to individuals in need of administration of such tablets.

    摘要翻译: 本文公开了包含施用此类片剂的片剂和治疗方法。 片剂是包含约400mg 5-甲基-2-(2'-氯-6'-氟苯胺基)苯乙酸或其药学上可接受的盐的速释片剂,其中5-甲基-2-(2'- 氯代-6'-氟苯胺基)苯乙酸或其药学上可接受的盐占片剂重量的60-70%。 所述方法涉及将本发明的片剂给予需要施用此类片剂的个体。

    METHOD OF TREATING METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETES
    2.
    发明申请
    METHOD OF TREATING METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETES 审中-公开
    治疗代谢障碍,特别是糖尿病或与糖尿病有关的疾病或病症的方法

    公开(公告)号:US20070275928A1

    公开(公告)日:2007-11-29

    申请号:US11781630

    申请日:2007-07-23

    摘要: The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises nateglinide (I) or repaglinide and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), sulfonyl urea derivatives and metformin for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of diseases, especially metabolic disorders and in particular type 2 diabetes and diseases and conditions associated with diabetes; to a composition, respectively, which comprises nateglinide and a pharmaceutically acceptable carrier and to a process of making such composition; the use of such combination or composition for the preparation of a medicament for the prevention, delay of progression or treatment of metabolic disorders; a method of prevention, delay of progression or treatment of diseases in warm-blooded animals; the use of such combination or composition for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight; and to a method of improving the bodily appearance of a warm-blooded animal.

    摘要翻译: 本发明涉及分别包含那格列奈(I)或瑞格列奈和至少一种选自噻唑烷二酮衍生物(格列酮),磺酰脲衍生物和二甲双胍的其它抗糖尿病化合物的组合,例如组合制剂或药物组合物 用于预防,延迟进展或治疗疾病,特别是代谢紊乱,特别是2型糖尿病和与糖尿病相关的疾病和病症的同时,单独或顺序使用; 涉及包含那格列奈和药学上可接受的载体的组合物和制备该组合物的方法; 使用这种组合或组合物来制备用于预防,延缓进展或治疗代谢紊乱的药物; 一种预防,延缓进展或治疗温血动物疾病的方法; 使用这样的组合或组合物来进行化妆品处理哺乳动物以实现美容上有益​​的体重损失; 以及改善温血动物的身体外观的方法。

    Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
    3.
    发明申请
    Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes 审中-公开
    治疗代谢紊乱,特别是糖尿病或与糖尿病有关的疾病或病症的方法

    公开(公告)号:US20050124663A1

    公开(公告)日:2005-06-09

    申请号:US11036842

    申请日:2005-01-14

    摘要: The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises nateglinide (I) or repaglinide and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), sulfonyl urea derivatives and metformin for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of diseases, especially metabolic disorders and in particular type 2 diabetes and diseases and conditions associated with diabetes; to a composition, respectively, which comprises nateglinide and a pharmaceutically acceptable carrier and to a process of making such composition; the use of such combination or composition for the preparation of a medicament for the prevention, delay of progression or treatment of metabolic disorders; a method of prevention, delay of progression or treatment of diseases in warm-blooded animals; the use of such combination or composition for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight; and to a method of improving the bodily appearance of a warm-blooded animal.

    摘要翻译: 本发明涉及分别包含那格列奈(I)或瑞格列奈和至少一种选自噻唑烷二酮衍生物(格列酮),磺酰脲衍生物和二甲双胍的其他抗糖尿病化合物的组合,例如组合制剂或药物组合物 用于预防,延迟进展或治疗疾病,特别是代谢紊乱,特别是2型糖尿病和与糖尿病相关的疾病和病症的同时,单独或顺序使用; 涉及包含那格列奈和药学上可接受的载体的组合物和制备该组合物的方法; 使用这种组合或组合物来制备用于预防,延缓进展或治疗代谢紊乱的药物; 一种预防,延缓进展或治疗温血动物疾病的方法; 使用这样的组合或组合物来进行化妆品处理哺乳动物以实现美容上有益​​的体重损失; 以及改善温血动物的身体外观的方法。